Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced...

Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020 - The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 29, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a...

Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European...

Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications - Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers - - Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and...